Neuronal circuit plasticity during development is fundamental for precise network formation. 25 Pioneering studies of the developmental visual cortex indicated that noradrenaline (NA) is 26 crucial for ocular dominance plasticity during the critical period in the visual cortex. Recent 27 research demonstrated tonotopic map formation by NA during the critical period in the auditory 28 system, indicating that NA also contributes to synaptic plasticity in this system. The lateral 29 superior olive (LSO) in the auditory system receives glutamatergic input from the ventral 30 cochlear nucleus (VCN) and undergoes circuit remodeling during postnatal development. 
Introduction
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filled with standard external solution containing 150 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2, 2 118 mM CaCl 2 , 10 mM glucose, and 10 mM HEPES (pH = 7.4) with a Tris base. The tip of a 119 fire-polished glass pipette was lightly placed on the surface of LSO and was vibrated 120 horizontally at 60 Hz (amplitude: 0.3-0.5 mm) for about 10 minutes using a custom-built 121 vibration device. The slices were then removed and the mechanically isolated neurons were 122 allowed to settle and to adhere to the bottom of the dish for 15 minutes. LSO neurons that 123 retained their original morphological features (diameter >20 μm, fusiform somata, bipolar and 124 multipolar dendritic processes) were used for the experiment. 125 
126
Electrophysiology 127 Electrophysiological recordings were made using a conventional whole-cell patch-clamp 128 recording technique with a holding potential of −60 mV for the voltage-clamp recordings and a 129 holding current of 0 pA for the current-clamp recordings (Multiclamp 700B; Molecular Devices). 130 The pipette solution contained 105 mM Cs-methanesulfonate, 35 mM CsCl, 0.6 mM EGTA, 10 131 mM HEPES, 4 mM ATP-Mg, 0.3 mM GTP-Na, 5 mM TEA-Cl, and 5 mM QX-314 (pH = 7.2) 132 with a Tris base for voltage-clamp recordings and 130 mM K-methanesulfonate, 10 mM KCl, 133 0.6 mM EGTA, 10 mM HEPES, 4 mM ATP-Mg, and 0.3 mM GTP-Na (pH = 7.2) with a Tris 134 8 calculated without failure events and taken as the single-fiber input strength for the cell. For 166 the measurement of maximum EPSC amplitude, responses were considered to be maximal if 167 a further increase in stimulus intensity led to a decline in response amplitudes or if the 168 responses remained unchanged over an approximately 100 μA increase in intensity. Mean 169 maximum peak amplitudes for the cell were calculated by averaging more than five responses 170 at the maximum stimulus intensity. 171 Patch pipettes were pulled from borosilicate glass capillaries (1.5 mm outer diameter, 0.9 172 mm inner diameter; GD-1.5; Narishige, Tokyo, Japan) on a pipette puller Sutter 173 Instrument Co., Novato, CA, USA). The pipettes had an open tip resistance of 3-5 MΩ. 174 Data were acquired using pCLAMP 9 software, filtered at 4 kHz, and digitized at 10 kHz 175 (Digidata 1320A; Molecular Devices). The series resistance (Rs) of 5-20 MΩ was 176 compensated by 70%-80% and continuously monitored throughout recordings. If the Rs 177 changed by more than 15% from its initial value, the data were discarded. No corrections 178 were made for liquid junction potentials. 179 
180
Chronic NA-lesioned or α 2 -adrenoceptor-blocked models 181 Balb/c mice were intraperitoneally injected with 182 N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4; 50 mg/kg) or vehicle 183 (saline) every two days from P2 to P8, or 2.5 mg/kg yohimbine hydrochloride every day from 184 P3 to P11. The mice underwent electrophysiological recordings at P5-P7 or P11-P13. 185 
186
Immunofluorescent staining 187 Immunofluorescent imaging was performed as described previously (Inada et al. 2011) . 188 In brief, mice were anesthetized and transcardially perfused with ice-cold phosphate buffered9 saline (PBS) and 4% (w/v) paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) (pH = 7.4) . 190 Brains were quickly removed and fixed overnight in 4% PFA/0.1 M PB. Next, coronal sections were made on a microslicer in the ice-cold PBS. Free-floating sections were 192 washed and then incubated for 30 min in 0.3% Triton X-100/PBS containing 10% normal goat 193 serum. Slices were then incubated over two nights with primary antibodies in the same 194 solution (rabbit anti-adrenaline α 2A receptor, 1:100, Neuromics, Edina, MN, USA; and guinea 195 pig anti-vesicular glutamate transporter 1 (VGLUT1), 1:200, Frontier Institute, Ishikari, 196 Hokkaido, Japan). After washing the primary antibodies, sections were incubated overnight 197 with secondary antibodies (goat anti-rabbit conjugated to Alexa Fluor 488 and goat 198 anti-guinea pig conjugated to Alexa Fluor 633, 1:300; Invitrogen, Carlsbad, CA, USA). 199 Fluorescent images were acquired with a confocal laser-scanning microscope (A1; Nikon, 200 Tokyo, Japan) using oil immersion objectives (100×/1.40 NA). The colocalization was 201 analyzed with NIH ImageJ software and then the ratio of the double-positive puncta to the 202 total VGLUT1-positive puncta was calculated. 203
204
Monoamine content measurement 205
High-performance liquid chromatography (HPLC) was used to measure monoamines as 206 described previously (Miyamoto et al. 2001) . Briefly, LSO was dissected out from brainstem 207 slices (300-μm thick) on an ice-cold glass dish. The tissue was rapidly frozen, measured by 208 weight and stored in a freezer at −80°C until assayed. The monoamine content was 209 determined using an HPLC system with an electrochemical detector (Eicom, Kyoto, Japan The drugs used were L-noradrenaline bitrate from Tokyo Chemical Industry (Tokyo, 227 Japan), DL-isoproterenol hydrochloride and yohimbine hydrochloride from Nacalai tesque 228 (Kyoto, Japan), (R)-(-)-phenylephrine hydrochloride from Wako Pure Chemical Industries 229 (Osaka, Japan), and SR-95531 hydrobromide from Tocris Bioscience (Bristol, UK). All other 230 salts and chemicals were acquired from Sigma (St. Louis, MO, USA). Final drug 231 concentrations were made up from stock solutions just before use. (1559) 232
RESULTS
233
Noradrenaline inhibits glutamatergic transmission in the immature To study the function of NA in glutamatergic neurotransmission in the immature LSO, we 235 performed slice patch-clamp recordings from the LSO neurons with stimulation of the LSO pathway. Afferent stimulation applied to ventral acoustic stria during P3-P7 elicited 237 EPSCs in LSO primary neurons with mean peak amplitude of 526.2 ± 88.9 pA (n = 14). 238 Perfusion of 10 μM NA for 3 minutes significantly decreased EPSC amplitude to 75.9 ± 11.7 239 pA (82.8% ± 2.0% inhibition, P < 0.05, one-way ANOVA [post hoc: Tukey HSD test]; Fig. 1, A  240 and B). The EPSC amplitude recovered after washing out of NA (422.6 ± 74.4 pA; Fig. 1, A  241 and B). The inhibitory effect of NA on the EPSC during P3-P7 saturated at 10 μM (IC 50 = 1.06 242 ± 0.34 μM, n = 5; Fig. 1C ). Paired stimulation of VCN afferents at an interval of 50 ms induced 243 two consecutive EPSCs in the LSO neurons with a mean paired pulse ratio (PPR) of 1.00 ± 244 0.07 (n = 14, P3-P7 mice; Fig. 1D ). PPR was significantly increased during NA application 245 (1.94 ± 0.35; n = 14, P < 0.05, Student's t-test; Fig. 1D ). The coefficient of variation (CV) of 246 EPSC amplitudes was also significantly increased by NA (control, 0.13 ± 0.01; NA, 0.40 ± 247 0.04, n = 14, P < 0.05, Student's t-test; Fig. 1E t-test, n = 13; Fig. 2B ), but not the amplitude (control, 33.6 ± 2.01 pA; NA, 32.2 ± 1.69 pA; P = 258 0.19, Student's t-test, n = 13; Fig. 2C ). In addition, in acutely isolated LSO neurons, NA failed 259 to reduce the currents induced by direct application of 100 μM glutamate (control, 79.8 ± 34.6 260 pA; NA, 78.8 ± 30.4 pA; after NA, 78.0 ± 33.2 pA; P = 0.78, n = 5, Friedman test; Fig. 2D) . 261 These results demonstrate that NA suppresses glutamate release from VCN-LSO terminals 262 but does not suppress postsynaptic glutamate response of immature LSO neurons. 263 We investigated the adrenoreceptor involved in the inhibition of glutamate release by NA 264 in immature VCN-LSO synapses using antagonists and agonists of three major types of 265 adrenoceptor. Yohimbine, an α 2 adrenoceptor antagonist, but not prazosin nor propranolol, α 1 266 and β antagonists, respectively, significantly interfered with NA modulation of EPSC amplitude 267 (NA without any antagonists, 81.8% ± 2.9% inhibition, n = 6; NA with 10 μM yohimbine, 19.6% 268 ± 5.5% inhibition, n = 6, P < 0.05; NA with 10 μM prazosin, 79.7% ± 2.1% inhibition, n = 6, P = 269 0.86; NA with 10 μM propranolol, 80.0% ± 4.7% inhibition, n = 6, P = 1.00, Kruskal-Wallis test 270 [post hoc: Steel test]; Fig. 3, A and B) . UK-14304, a specific α 2 adrenoceptor agonist, but not 271 phenylephrine and isoproterenol, α 1 and β agonists, respectively, mimicked NA action 272 (UK-14304, 75.5% ± 2.7% inhibition, n = 6, P = 0.34; phenylephrine, 19.7% ± 3.7% inhibition, 273 n = 6, P < 0.05; isoproterenol, 3.0% ± 6.4% inhibition, n = 5, P < 0.05, Kruskal-Wallis test 274 [post hoc: Steel test]; Fig. 3, C and D) . In addition, yohimbine significantly blocked the 275 increase in PPR by NA (yohimbine, 1.34 ± 0.10, n = 6; NA with yohimbine, 1.37 ± 0.05, n = 6, 276 P = 0.75, Wilcoxon signed rank test), and UK-14304 mimicked the action of NA on PPR 277 (control, 1.17 ± 0.08, n = 6; UK-14304, 1.52 ± 0.03, n = 6, P < 0.05, Wilcoxon signed rank test). 278 No other antagonists or agonists affected the effect of NA on PPR (prazosin, 1.05 ± 0.06, n = 279 6; NA with prazosin, 1.28 ± 0.05, n = 6, P < 0.05; propranolol, 1.14 ± 0.08, n = 6; NA with13 propranolol, 1.46 ± 0.09, n = 6, P < 0.05; control, 0.97 ± 0.07, n = 6; phenylephrine, 1.05 ± 281 0.08, n = 6, P = 0.06; control, 1.08 ± 0.06, n = 5; isoproterenol, 1.08 ± 0.04, n = 5, P = 1.00, 282 Wilcoxon signed rank test). Therefore, the inhibition of glutamate release by NA is mediated 283 by activation of α 2 adrenoceptors. Finally, we examined whether α 2 adrenoceptors are located 284 presynaptically or postsynaptically. To do this, recording was performed in the presence of 285 GDP-βS, an inhibitor of G protein-coupled signaling, in the recording pipette. GDP-βS did not 286 affect the inhibition of EPSCs and the increase in PPR by UK-14304 (EPSC amplitude: 287 control, 287.9 ± 94.2 pA; UK-14304, 99.6 ± 29.6 pA; n = 5, P < 0.05, PPR: control, 0.94 ± 288 0.07; UK-14304, 1.26 ± 0.08; n = 5, P < 0.05, Wilcoxon signed rank test, Fig. 3E ). These data 289 suggest that the suppression of EPSCs by NA is mediated by activation of presynaptic α 2 290 adrenoceptors and subsequent inhibition of glutamate release. 291
292
Long-term application of NA induces long lasting EPSC suppression 293 The inhibitory effect of UK-14304 applied for 15 minutes continued for a long time after 294 washout of the agonist by an application of competitive α 2 adrenoceptor antagonist in Fig. 3E 295 (EPSC amplitude: control, 287 .9 ± 94.2 pA; post yohimbine, 176.8 ± 56.4 pA; n = 5, p < 0.05, 296 PPR: control, 0.94 ± 0.07; post yohimbine, 1.14 ± 0.09; n = 5, p < 0.05, Wilcoxon signed rank 297 test). In addition, we sometimes observed a phenomenon that washout of NA did not 298 completely return EPSC amplitude to the control level despite rapid recovery (see Fig. 1, A  299 and B). These suggest a long-term effect of presynaptic α 2 adrenoceptors and NA. Therefore, 300 we measured EPSCs before long-term NA application and after NA washout. Application of 301 NA for 15 minutes induced long-term suppression of EPSCs (control, 287.3 ± 56.6 pA; post 302 NA washout, 102.1 ± 37.5 pA; n = 5, P < 0.05, Wilcoxon signed rank test; Fig. 4A ) together 303 with an increase in the PPR (control, 1.00 ± 0.11; post NA washout, 1.27 ± 0.11; n = 5, P <14 0.05, Wilcoxon signed rank test; Fig. 4A ). This result was mimicked by application of 305 UK-14304 for 15 minutes (EPSC amplitude: control, 207.1 ± 52.8 pA; post UK-14304 washout, 306 73.0 ± 26.2 pA; n = 6, P < 0.05, PPR: control, 0.83 ± 0.09; post UK-14304 washout, 1.12 ± 307 0.12; n = 6, P < 0.05, Wilcoxon signed rank test; Fig. 4B Because a dramatic developmental change of presynaptic metabotropic glutamate 313 receptor 2/3 was observed in the LSO in our previous study (Nishimaki et al. 2007 ), we 314 examined developmental change of the NA action. Interestingly, the ability of NA to reduce 315 EPSC amplitude declined progressively during 1-2 weeks after birth (R = −0.86, P < 0.05, 316
Pearson's product-moment correlation coefficient; Fig. 5A ). Immunohistology showed that the 317 fraction of VGLUT1-positive puncta in the LSO that were double-labeled for VGLUT1 and α 2A 318
adrenoceptor also decreased between P5-P7 and P12-P14 (P5-P7, 21.7% ± 2.6 %, n = 6; 319 P12-P14, 6.1% ± 1.0 %, n = 5, P < 0.05, Mann-Whitney U-test; see also adrenoceptors. Intraperitoneal DSP-4 injection during the early postnatal period caused a 335 significant decrease in NA content in the LSO at P14 (saline, 108.9 ± 14.9 ng/mg wet tissue, 336 DSP-4, 68.1 ± 12.3 ng/mg wet tissue, n = 10 each group, P < 0.05, Student's t-test). However, 337 it did not cause a significant decrease in dopamine (saline, 14.8 ± 2.3 ng/mg wet tissue, 338 DSP-4, 13.6 ± 2.2 ng/mg wet tissue, n = 10 each; P = 0.72, Student's t-test) or serotonin 339
(5-HT) content (saline, 157.9 ± 31.6 ng/mg wet tissue, DSP-4, 125.2 ± 27.4 ng/mg wet tissue, 340 n = 10 each, P = 0.45, Student's t-test). This result suggests that DSP-4 preferentially 341 impaired NA afferents in the immature LSO. 342 Next we tested the general development of mice injected with DSP-4 and yohimbine. 343 Chronic DSP-4 injection affected weight gain (saline at P10, 6.89 ± 0.38 g, n = 11; DSP-4 at 344 P10, 5.73 ± 0.15 g, n = 11, P < 0.05, Mann-Whitney U-test; Fig. 6A ) but chronic application 345 of yohimbine did not affect body weight (saline at P11, 8.15 ± 0.21 g, n = 10; DSP-4 at P11, 346 7.46 ± 0.35 g, n = 12, P = 0.12, Mann-Whitney U-test; Fig. 6B ). Injection of drugs did not 347 significantly affect brain weight at P11-P13 (saline, 395.3 ± 4.0 mg, n = 11; DSP-4, 379.3 ± 348 5.0 mg, n = 11, P = 0.06; Fig. 6C ; saline, 404.5 ± 3.4 mg, n = 11; yohimbine, 400.0 ± 4.2 mg, n 349 = 11, P = 0.43, Mann-Whitney U-test; Fig. 6D ). These results indicate that DSP-4 and 350 yohimbine do not seem to affect brain growth. Further, we examined membrane properties of 351 the LSO neurons of drug-treated mice. The resting membrane potential of the recorded cells 352 was not significantly different (saline, −59.9 ± 0.8 mV, n = 19; DSP-4, −59.1 ± 0.9 mV, n = 10, 353 P = 0.91; yohimbine, −61.9 ± 1.1 mV, n = 10, P = 0.61, Kruskal-Wallis test). In addition, we did 354 not detect any difference among groups treated with saline, DSP-4, or yohimbine, with 355 respect to input resistance of all recorded cells (saline, 176.6 ± 16.5 MΩ, n = 19; DSP-4, 163.1 356 ± 15.3 MΩ, n = 10, P = 1.00; yohimbine, 196.5 ± 28.7 MΩ, n = 10, P = 0.78, Kruskal-Wallis 357 test), or the current-voltage response curve (Fig. 6, E-G) . These results suggest that DSP-4 358 and yohimbine do not affect passive and active membrane properties of LSO neurons. 359 Subsequently, we evaluated the effect of endogenous NA and α 2 adrenoceptor activation 360 on functional elimination of VCN-LSO afferent fibers. EPSC amplitudes recorded from P5-P7 361 mice progressively increased as stimulus intensity increased (n = 5, Fig. 7A ). This is 362 consistent with the idea that LSO neurons are innervated by a large number of VCN fibers at 363 the early postnatal age. On the other hand, at P11-P13, eight out of nine cells showed EPSC 364 amplitudes that increased in discrete steps in response to increasing stimulus intensities (Fig.  365 7B). The number of steps in EPSC amplitude determined by cluster analysis (see Methods) 366 varied between two and four (average 2.7 ± 0.9, n = 8; Fig. 7E ). This result suggests that each 367 LSO neuron is innervated by only a couple of VCN fibers around the time of hearing onset, as 368 previously reported (Case et al. 2011) . In contrast, in mice treated with DSP-4 and yohimbine, 369 EPSC amplitudes recorded from P11-P13 gradually increased (DSP-4, n = 5, yohimbine, n = 370 6; Fig. 7, C and D) . The number of steps in EPSC amplitude could not be counted in any 371 DSP-4-treated mice and in five of six yohimbine-treated mice (Fig. 7E) , because of the low 372 silhouette index (refer to Kim and Kandler 2003) . Therefore, LSO neurons of mice injected 373 with DSP-4 and yohimbine are innervated by a large number of VCN axons even at P11-P13, 374 as observed in saline-treated mice at P5-P7. This result indicates that endogenous NA and 375 activation of α 2 adrenoceptors contribute to functional elimination of VCN afferents in theimmature LSO. 377 Finally, we studied the effect of endogenous NA and α 2 adrenoceptor activation on 378 functional strengthening of VCN-LSO afferents. The maximum input strength of inputs in P11-P13 saline-treated mice (mean: 937.1 ± 84.9 pA, median: 837.5 pA, n = 8, Fig.  380 7F) was significantly higher than that in P5-P7 saline-treated mice (mean: 343.9 ± 68.5 pA, 381 median: 343.8 pA, n = 10, P < 0.05, Kruskal-Wallis test [post hoc: Steel test]; Fig. 7F) . 382 However, mice injected with DSP-4 and yohimbine showed significantly lesser strength at 383 P11-P13 than saline-treated mice at the same age (DSP-4, mean: 373.2 ± 82.5 pA, median: 384 337.8 pA, n = 5, P < 0.05; yohimbine, mean: 339.9 ± 77.2, median: 339.9 pA, n = 6, P < 0.05, Taken together, the results in the present study indicate that NA is required for the
In the present study, we investigated the role of NA in the development of the VCN-LSO 398 glutamatergic pathway. First, we demonstrated inhibitory action of NA on EPSC in the LSO pathway during the first postnatal week. Subsequent experiments indicated that the 400 inhibitory effect was preferentially mediated by suppression of presynaptic glutamate release 401 through activation of presynaptic α 2 adrenoceptors, the G protein-coupled receptor (GPCR) 402 that is linked to the G αi/o subunit. Because the βγ subunit of GPCR blocks N-type and 403 P/Q-type voltage-gated calcium channels (VGCCs) (Herlitze et al. 1996; Ikeda 1996) , which 404 are abundantly expressed in immature auditory brainstem (Iwasaki and Takahashi 1998) and 405 contribute to presynaptic neurotransmitter release (for review, see Reid et al. 2003) , the 406 inhibition of glutamate release by α 2 adrenoceptors is mediated by blockade of VGCCs on 407 VCN-LSO terminals. 408 We then showed that long-term application of NA induced a persistent suppression of 409 EPSCs accompanied by an increase in PPR, potentially through activation of presynaptic α 2 410
adrenoceptors. The mechanism of the long-term suppression of NA is still unclear. suppression through activation of α 2 adrenoceptors and some of these mechanisms on 416 presynaptic terminals. 417 We further demonstrated that the inhibitory effect of NA gradually decreased during the 418 first two postnatal weeks, which was correlated with a decrease in α 2A adrenoceptors onand α 2C (Lorenz et al. 1990 indicate that the dramatic changes in the auditory circuit around the time of hearing onset 437 might occur for high-fidelity transmission of higher frequency sound information. Therefore, 438 the developmental disappearance of the EPSC suppression by NA helps to establish robust 439 circuits. 440 Because the VCN-LSO pathway undergoes functional refinement before hearing onset 441 (Case et al. 2011), we examined whether endogenous NA affects the functional maturation of 442 the circuit. NA afferents in the LSO originate from the locus coeruleus (Woods and Azaredodischarge in the early postnatal weeks (Nakamura et al. 1987) . To deplete the noradrenergic 445 system originating from the locus coeruleus before hearing onset, we intraperitoneally 446 injected DSP-4 into mice every two days from P2-P8. DSP-4 is a selective and long-lasting 447 neurotoxin for noradrenergic neurons (Jonsson et al. 1981; Fritschy et al. 1990 ), which has 448 been used to investigate the functions of the central noradrenergic system (Daw et al. 1985; 449 Matsukawa et al. 2003) . The toxin has a high selectivity for locus coeruleus noradrenergic 450 systems because of a high affinity for its NA reuptake system (Cassano et al. 2009 ). In the 451 present study, intraperitoneal injection of DSP-4 delayed weight gain during the postnatal 452 period, similar to previous findings in dopamine β-hydroxylase knock-out mice, which 453 completely lack NA from birth (Shepard et al. 2015) . However, the brain weight at P11-P13 454 was comparable with the saline-treated mice, suggesting a role of NA in food intake, but not 455 brain growth. In addition to DSP-4, to test the effect of α 2 adrenoceptor inhibition on the 456 functional maturation of the circuit, we injected another group of mice with yohimbine every 457 day from P3-P11. Mice injected with DSP-4 or yohimbine before hearing onset showed lack 458 of the functional refinement of VCN-LSO synapses. Because the inhibition of EPSCs by NA is 459 preferentially mediated by presynaptic mechanisms, the lack of developmental refinement 460 was possibly due to disruption of NA-induced inhibitory action on glutamate release through 461 activation of presynaptic α 2 adrenoceptors at VCN afferent terminals on LSO neurons. 462 However we cannot exclude other mechanisms. For instance, locus coeruleus NA neurons 463 also project to the cochlear nucleus (Kromer and Moore 1976). NA enhances the 464 signal-to-noise ratio of feed forward inhibition from granule cells to fusiform principal cells in 465 the dorsal cochlear nucleus through activation of postsynaptic α 2 adrenoceptors on 466 glycinergic interneurons, inhibiting spontaneous firing of the neurons and suppressing tonicof NA neurotoxin or α 2 adrenoceptor antagonists affects the noradrenergic system throughout 469 the brain, cochlear nucleus output might be affected by these manipulations, resulting in the 470 changed pattern of spontaneous activity in the downstream auditory pathway. Further studies 471 are necessary to clarify this effect. 472 The mechanism of refinement through presynaptic α 2 adrenoceptors on VCN terminals is 473 also unclear. Previous studies indicated that the elimination of axon terminals and the pruning These indicate a possibility that α 2 adrenoceptors are regulated in an activity-dependent 489 manner. Altogether, these findings suggest that NA might work as a filter for functional
In conclusion, the results of the present study suggest that NA has a crucial role in the 492 refinement of the VCN-LSO glutamatergic pathway. A recent study demonstrated that 493 dopamine β-hydroxylase knock-out mice showed loss of experience-dependent tonotopic 494 map plasticity during the cortical auditory critical period (Shepard et al. 2015 This work was supported by Grant-in-Aid for Scientific Research (A), 2013-2016 (25253017, 506 Junichi Nabekura), Grant-in-Aid for Scientific Research (C), 2009 -2011 Ishibashi), and Grant-in-Aid for Scientific Research (C), 2012 -2015 Ishibashi). 
